Skip to main content

Advertisement

SpringerLink
Log in

Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites. We conducted this experimental study to find out if bevacizumab, a humanized monoclonal antibody against VEGF, had a suppressive effect on peritoneal dissemination from gastric cancer, in an experimental nude mouse model of peritoneal metastasis.

Methods

Each mouse was treated with a single intraperitoneal (i.p.) injection of bevacizumab. Five mice were killed, and we measured their body weight, the mean number of tumor nodules, and the volume of ascites. We also extracted retroperitoneal tissues for histological examination, to count the frequency of mitosis, and to calculate the mitotic index. Another five mice were monitored until death, and their mean survival duration was calculated.

Results

The volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group (P = 0.042 and P < 0.01, respectively). The survival curve of the therapy group was significantly higher than that of the nontherapy group (P = 0.005).

Conclusion

Bevacizumab may suppress peritoneal dissemination from gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.

    Article  CAS  PubMed  Google Scholar 

  2. Ikeguchi M, Miyake T, Matsunaga T, Yamamoto M, Fukumoto Y, Yamada Y, et al. Recent results of therapy for scirrhous gastric cancer. Surg Today 2009;39:290–294.

    Article  CAS  PubMed  Google Scholar 

  3. Yonemura Y, Endou Y, Yamaguchi T. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncol 1996;8:795–802.

    Google Scholar 

  4. Yonemura Y. Peritoneal dissemination. Tokyo: Health Publishers; 1996.

    Google Scholar 

  5. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix. Cancer Res 1986;46:1–7.

    Article  CAS  PubMed  Google Scholar 

  6. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373–378.

    Article  CAS  PubMed  Google Scholar 

  7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;50:1209–1239.

    Google Scholar 

  8. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224–5229.

    CAS  PubMed  Google Scholar 

  9. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005;8:155–163.

    Article  CAS  PubMed  Google Scholar 

  10. Miyagi M, Aoyagi K, Kato S, Shirouzu K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol 2007;12:17–24.

    Article  CAS  PubMed  Google Scholar 

  11. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey Y, Dvorak HF. Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.

    Article  CAS  PubMed  Google Scholar 

  12. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851–858.

    Article  CAS  PubMed  Google Scholar 

  13. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902–906.

    Article  CAS  PubMed  Google Scholar 

  14. Uenomori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:357–362.

    Google Scholar 

  15. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412–5416.

    CAS  PubMed  Google Scholar 

  16. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Klk-1/FDR activation. J Biol Chem 1998;273:30336–30343.

    Article  CAS  PubMed  Google Scholar 

  17. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, et al. Abnormally enhanced blood concentrations of vascular growth factors (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001;15:140–144.

    CAS  PubMed  Google Scholar 

  18. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008;14:6371–6375.

    Article  CAS  PubMed  Google Scholar 

  19. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447–454.

    Article  CAS  PubMed  Google Scholar 

  20. Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into Lo Vo human colon cancer cell line. Clin Cancer Res 2000;6:622–630.

    CAS  PubMed  Google Scholar 

  21. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 2000;7:1027–1033.

    Article  CAS  PubMed  Google Scholar 

  22. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360–368.

    CAS  PubMed  Google Scholar 

  23. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusion of patients with malignant and nonmalignant disease. Cancer 1999;85:178–187.

    Article  CAS  PubMed  Google Scholar 

  24. Mesiano S, Ferrara N, Jaffe RB. Role of vascular growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249–1256.

    CAS  PubMed  Google Scholar 

  25. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979–1986.

    Article  CAS  PubMed  Google Scholar 

  26. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.

    Article  CAS  PubMed  Google Scholar 

  27. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729–2735.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan

    Takuya Imaizumi, Keishiro Aoyagi, Motoshi Miyagi & Kazuo Shirouzu

Authors
  1. Takuya Imaizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keishiro Aoyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motoshi Miyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuo Shirouzu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imaizumi, T., Aoyagi, K., Miyagi, M. et al. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today 40, 851–857 (2010). https://doi.org/10.1007/s00595-009-4154-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-009-4154-y

Key words

Search

Navigation